IRIS
VICENTI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.308
EU - Europa 6.202
AS - Asia 3.193
SA - Sud America 624
Continente sconosciuto - Info sul continente non disponibili 309
AF - Africa 213
OC - Oceania 9
Totale 17.858
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.158
RU - Federazione Russa 1.400
IT - Italia 1.259
GB - Regno Unito 1.042
SG - Singapore 1.022
CN - Cina 822
IE - Irlanda 740
BR - Brasile 507
DE - Germania 417
VN - Vietnam 402
SE - Svezia 371
HK - Hong Kong 318
FR - Francia 310
FI - Finlandia 176
UA - Ucraina 168
IN - India 143
KR - Corea 141
ZA - Sudafrica 121
ES - Italia 79
BD - Bangladesh 77
CA - Canada 73
MX - Messico 44
NL - Olanda 41
JP - Giappone 40
TR - Turchia 40
AR - Argentina 39
PL - Polonia 37
IQ - Iraq 34
BE - Belgio 33
NG - Nigeria 31
AT - Austria 30
ID - Indonesia 17
PK - Pakistan 17
CZ - Repubblica Ceca 16
UZ - Uzbekistan 16
CO - Colombia 15
EC - Ecuador 14
KE - Kenya 14
LT - Lituania 13
IR - Iran 12
JM - Giamaica 12
PY - Paraguay 12
VE - Venezuela 12
MA - Marocco 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
CI - Costa d'Avorio 9
SA - Arabia Saudita 9
DK - Danimarca 8
EG - Egitto 8
LV - Lettonia 8
EE - Estonia 7
GR - Grecia 7
TH - Thailandia 7
AU - Australia 6
AZ - Azerbaigian 6
JO - Giordania 6
NP - Nepal 6
PH - Filippine 6
PT - Portogallo 6
BO - Bolivia 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
HN - Honduras 5
PA - Panama 5
PE - Perù 5
BG - Bulgaria 4
ET - Etiopia 4
GE - Georgia 4
SN - Senegal 4
TW - Taiwan 4
AL - Albania 3
CR - Costa Rica 3
IL - Israele 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
LK - Sri Lanka 3
MY - Malesia 3
PS - Palestinian Territory 3
RO - Romania 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BW - Botswana 2
BY - Bielorussia 2
CY - Cipro 2
DZ - Algeria 2
GY - Guiana 2
HU - Ungheria 2
KH - Cambogia 2
LU - Lussemburgo 2
NO - Norvegia 2
TN - Tunisia 2
AM - Armenia 1
AO - Angola 1
BZ - Belize 1
Totale 17.534
Salva come PNG Salva come JPEG
Città #
Southend 848
Dallas 811
Dublin 733
Singapore 582
Ashburn 535
Fairfield 529
San Jose 509
Chandler 443
Santa Clara 402
Moscow 375
Hong Kong 304
Milan 266
Siena 233
Beijing 228
Council Bluffs 228
Woodbridge 225
Munich 222
Seattle 220
Ann Arbor 216
Houston 199
Cambridge 187
Hefei 174
Wilmington 169
New York 144
Los Angeles 141
Seoul 137
Rome 136
Ho Chi Minh City 129
Jacksonville 129
Princeton 117
Johannesburg 115
Helsinki 93
Lauterbourg 90
Hanoi 89
The Dalles 73
Boardman 51
Bengaluru 50
Florence 49
São Paulo 48
Columbus 45
Málaga 44
San Diego 44
Shanghai 44
Orem 42
Buffalo 41
San Mateo 38
London 36
Tokyo 32
Brussels 31
Frankfurt am Main 31
Redondo Beach 31
Turku 31
Warsaw 30
Abuja 29
Nanjing 29
Portsmouth 29
Chicago 28
Nuremberg 26
Lappeenranta 25
Montreal 25
Brooklyn 24
Chennai 23
Denver 23
Dong Ket 22
Naples 22
Dearborn 21
Mexico City 21
Vienna 21
Atlanta 20
Manchester 20
Phoenix 20
Figino 19
Stockholm 19
Toronto 19
Haiphong 17
San Francisco 17
Düsseldorf 16
Fremont 16
Nanchang 16
Turin 16
Rio de Janeiro 15
Brescia 14
Da Nang 14
Guangzhou 14
Newark 14
Poplar 14
Washington 14
Amsterdam 13
Brasília 13
Changsha 13
Baghdad 12
Dhaka 12
Tashkent 12
Belo Horizonte 11
Hải Dương 11
Mumbai 11
North Bergen 11
Perugia 11
Redwood City 11
Ankara 10
Totale 11.582
Salva come PNG Salva come JPEG
Nome #
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 339
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients 339
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 310
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 310
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 307
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 293
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 292
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 284
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 270
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 269
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 267
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 261
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 261
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 261
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 258
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 255
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 254
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 248
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 248
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 248
Evidence of differential selection of HIV-1 variants carrying drug resistant mutations in seroconverters 241
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 238
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 234
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 233
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 224
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 224
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 220
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 216
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 212
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 212
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 209
Serendipitous identification of azine anticancer agents using a privileged scaffold morphing strategy 207
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 206
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 201
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in Tuscany, Italy 198
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 198
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 197
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 195
Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses 193
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 192
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro 191
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 188
Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3 188
Rules-based HIV-1 genotypic resistance interpretation systems predict 8-week and 24-week virological antiretroviral treatment outcome and benefit from drug potency weighting 187
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database 187
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 183
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 183
SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season 179
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 179
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 178
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity 174
Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic 172
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy 171
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 170
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage 169
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 169
Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties 168
Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination 164
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021 164
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects. 163
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 159
SARS-CoV2 infection in human testis and sperm: in vivo and in vitro studies 158
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 156
Zika virus in west africa: A seroepidemiological study between 2007 and 2012 156
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 155
SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells 154
Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm) 153
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 153
BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects 151
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 151
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 149
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization 147
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype 146
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 146
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 144
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 142
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 139
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 137
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility 137
HIV-1 Integrase Inhibition Activity by Spiroketals Derived from Plagius flosculosus, an Endemic Plant of Sardinia (Italy) and Corsica (France) 129
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 129
Serum neutralizing activity against b.1.1.7, b.1.351, and p.1 sars-cov-2 variants of concern in hospitalized covid-19 patients 128
Switching the three-component Biginelli-like reaction conditions for the regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines 125
Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection 123
null 121
Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021 120
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 117
null 114
Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy’s outcome for HIV-1 98
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 96
Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020 75
Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration 74
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro 71
Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012 58
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 38
null 32
null 14
null 12
Totale 17.858
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.784
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.784
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022941 0 0 0 161 66 65 71 71 69 109 110 219
2022/20231.426 78 204 166 164 126 270 69 100 97 61 63 28
2023/20241.197 38 36 101 77 21 307 408 35 8 26 34 106
2024/20252.978 67 99 377 183 288 231 110 207 319 158 295 644
2025/20266.978 476 832 779 899 1.411 241 761 227 285 387 207 473
2026/2027884 243 146 415 80 0 0 0 0 0 0 0 0
Totale 17.858